View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
October 28, 2009

Abbott Applies for New Humira Indication in Japan

Abbott Japan and Eisai have submitted an application for marketing authorisation for an additional application of Humira as a treatment for ankylosing spondylitis in Japan. Ankylosing spondylitis is a chronic inflammatory disease characterised by joint pain and stiffness followed by the d

By cms admin

Abbott Japan and Eisai have submitted an application for marketing authorisation for an additional application of Humira as a treatment for ankylosing spondylitis in Japan.

Ankylosing spondylitis is a chronic inflammatory disease characterised by joint pain and stiffness followed by the development of fusion and rigidity in affected joints, for which there is no specific cure.

The approval request is for Humira, a fully human monoclonal anti-TNF antibody jointly developed by the two companies in Japan, in a pre-filled syringe 40mg/0.8 mL for subcutaneous injection.

If approved, ankylosing spondylitis will be the fourth indication for Humira, following rheumatoid arthritis, psoriasis vulgaris and psoriatic arthritis, and Crohn’s disease.

The request is based on clinical studies in patients with active ankylosing spondylitis in Japan, where Humira demonstrated excellent efficacy in improving the signs and symptoms of ankylosing spondylitis and showed tolerability equivalent to that observed in foreign studies.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU